Skip to main content
Top
Published in: Advances in Therapy 7/2018

01-07-2018 | Brief Report

Unlicensed and Off-Label Medication Use in Pediatric and Neonatal Intensive Care Units: No Change Over a Decade

Authors: Hadar Nir-Neuman, Ibrahim Abu-Kishk, Michal Toledano, Eli Heyman, Tomer Ziv-Baran, Matitiahu Berkovitch

Published in: Advances in Therapy | Issue 7/2018

Login to get access

Abstract

Introduction

Many of the medications prescribed to children are off-label and/or unlicensed because pharmacologic evaluations have not been performed in this age group.

Methods

All drugs prescribed to patients admitted to the neonatal intensive care units (NICU) (n = 134) and pediatric intensive care units (PICU) (n = 56) during a 2-month observation period were recorded and classified according to patient age, drug license status, indicated use, and typical dosing, frequency and way of administration. Results were compared with prior data collected in 2002, from the same units.

Results

In the NICU, among the 1064 prescriptions for 49 medications, 312 (29.2%) were licensed and 63 (5.9%) unlicensed, and 693 (64.8%) were off-label use. For the neonates, 23.9% and 96.3% received at least one unlicensed medication and one off-label medication, respectively. While the difference in off-label use between the two time periods was not statistically significant, unlicensed medications were less frequently prescribed in 2016 (5.9 versus 16.6%, p = 0.001). Regarding the PICU, among the 388 prescriptions for 75 medications, 205 (52%) were licensed and 13 (3.4%) unlicensed, and 170 (43.8%) were off-label. In contrast, in 2002, none of the medications prescribed were unlicensed (p = 0.001). The number of off-label medications (41%) and number of PICU patients receiving at least one unlicensed/off-label medication in these two time periods (88.7% versus 90.5% for 2016 and 2002, respectively) were similar.

Conclusions

The current study confirms the high prevalence of unlicensed and off-label drug use in a PICU and NICU setting. Compared with a similar study conducted in the same PICU in 2002, despite regulatory efforts conducted in this area, the prevalence of unlicensed medications was surprisingly higher.
Literature
1.
go back to reference Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. N Engl J Med. 1960;262:787–94.CrossRefPubMed Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. N Engl J Med. 1960;262:787–94.CrossRefPubMed
2.
go back to reference Silverman WA, Andersen DH, Blanc WA, Crozier DN. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics. 1956;18(4):614–25.PubMed Silverman WA, Andersen DH, Blanc WA, Crozier DN. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics. 1956;18(4):614–25.PubMed
3.
go back to reference Gazarian M. Why are children still therapeutic orphans? Aust Prescr. 2003;26(6):122–3.CrossRef Gazarian M. Why are children still therapeutic orphans? Aust Prescr. 2003;26(6):122–3.CrossRef
4.
go back to reference Frattarelli DA, Galinkin JL, Green TP, et al. American Academy of Pediatrics Committee on Drugs. Off-label use of drugs in children. Pediatrics. 2014;133(3):563–7.CrossRefPubMed Frattarelli DA, Galinkin JL, Green TP, et al. American Academy of Pediatrics Committee on Drugs. Off-label use of drugs in children. Pediatrics. 2014;133(3):563–7.CrossRefPubMed
5.
go back to reference Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161:282–90.CrossRefPubMed Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161:282–90.CrossRefPubMed
6.
go back to reference McKinzie JP, Wright SW. Wrenn KD Pediatric drug therapy in the emergency department: does it meet FDA-approved prescribing guidelines? Am J Emerg Med. 1997;15(2):118–21.CrossRefPubMed McKinzie JP, Wright SW. Wrenn KD Pediatric drug therapy in the emergency department: does it meet FDA-approved prescribing guidelines? Am J Emerg Med. 1997;15(2):118–21.CrossRefPubMed
8.
go back to reference Turner S, Gill A, Nunn T, Hewitt B, Choonara I. Use of “off-label” and unlicensed drugs in paediatric intensive care unit. Lancet. 1996;347(9000):549–50.CrossRefPubMed Turner S, Gill A, Nunn T, Hewitt B, Choonara I. Use of “off-label” and unlicensed drugs in paediatric intensive care unit. Lancet. 1996;347(9000):549–50.CrossRefPubMed
9.
go back to reference Conroy S, McIntyre J, Choonara I. Unlicensed and off-label drug use in neonates. Arch Dis Child Fetal Neonatal. 1999;Ed 80(2):F142–144 (discussion F144–145). Conroy S, McIntyre J, Choonara I. Unlicensed and off-label drug use in neonates. Arch Dis Child Fetal Neonatal. 1999;Ed 80(2):F142–144 (discussion F144–145).
10.
go back to reference Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C. The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr. 2000;7(2):143–7.CrossRefPubMed Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C. The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr. 2000;7(2):143–7.CrossRefPubMed
11.
go back to reference Jong GW, van der Linden PD, Bakker EM, van der Lely N, Eland IA, Stricker B, et al. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol. 2002; 58(4):293–7. Jong GW, van der Linden PD, Bakker EM, van der Lely N, Eland IA, Stricker B, et al. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol. 2002; 58(4):293–7.
12.
go back to reference Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004;27(13):1059–67.CrossRefPubMed Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004;27(13):1059–67.CrossRefPubMed
13.
go back to reference Hsien L, Breddemann A, Frobel A-K, Heusch A, Schmidt K, LÃer S. Off-label drug use among hospitalised children: identifying areas with the highest need for research. Pharm World Sci. 2008;30(5):497–502.CrossRefPubMed Hsien L, Breddemann A, Frobel A-K, Heusch A, Schmidt K, LÃer S. Off-label drug use among hospitalised children: identifying areas with the highest need for research. Pharm World Sci. 2008;30(5):497–502.CrossRefPubMed
14.
go back to reference Di Paolo ER, Stoetter H, Cotting J, Frey P, Gehri M, Beck-Popovic M, et al. Unlicensed and off-label drug use in a Swiss paediatric university hospital. Swiss Med Wkly. 2006;136(13–14):218–22.PubMed Di Paolo ER, Stoetter H, Cotting J, Frey P, Gehri M, Beck-Popovic M, et al. Unlicensed and off-label drug use in a Swiss paediatric university hospital. Swiss Med Wkly. 2006;136(13–14):218–22.PubMed
15.
go back to reference Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther. 2009;34(3):277–87.CrossRefPubMed Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther. 2009;34(3):277–87.CrossRefPubMed
16.
go back to reference Lindell-Osuagwu L, Hakkarainen M, Sepponen K, Vainio K, Naaranlahti T, Kokki H. Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation. J Clin Pharm Ther. 2014;39(2):144–53.CrossRefPubMed Lindell-Osuagwu L, Hakkarainen M, Sepponen K, Vainio K, Naaranlahti T, Kokki H. Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation. J Clin Pharm Ther. 2014;39(2):144–53.CrossRefPubMed
17.
go back to reference Zanon D, Gallelli L, Rovere F, Paparazzo R, Maximova N, Lazzerini M, et al. Off-label prescribing patterns of antiemetics in children: a multicenter study in Italy. Eur J Pediatr. 2013;172:361–7.CrossRefPubMed Zanon D, Gallelli L, Rovere F, Paparazzo R, Maximova N, Lazzerini M, et al. Off-label prescribing patterns of antiemetics in children: a multicenter study in Italy. Eur J Pediatr. 2013;172:361–7.CrossRefPubMed
18.
go back to reference Ribeiro M, Jorge A, Macedo A. Off-label drug prescribing in a Portuguese. Paediatric Emergency Unit. Int J Clin Pharm. 2013;35:30–6. Ribeiro M, Jorge A, Macedo A. Off-label drug prescribing in a Portuguese. Paediatric Emergency Unit. Int J Clin Pharm. 2013;35:30–6.
19.
go back to reference Palčevski G, Skočibušić N, Vlahović-Palčevski V. Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey. Eur J Clin Pharmacol. 2012;68(7):1073–7.CrossRefPubMed Palčevski G, Skočibušić N, Vlahović-Palčevski V. Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey. Eur J Clin Pharmacol. 2012;68(7):1073–7.CrossRefPubMed
20.
go back to reference Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off-label drug use in paediatric wards in European countries. BMJ. 2000;320(7227):79–82.CrossRefPubMedPubMedCentral Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off-label drug use in paediatric wards in European countries. BMJ. 2000;320(7227):79–82.CrossRefPubMedPubMedCentral
21.
go back to reference Craig JS, Henderson CR, Magee FA. The extent of unlicensed and off-label drug use in the paediatric ward of a district general hospital in Northern Ireland. Ir Med J. 2001;94(8):237–40.PubMed Craig JS, Henderson CR, Magee FA. The extent of unlicensed and off-label drug use in the paediatric ward of a district general hospital in Northern Ireland. Ir Med J. 2001;94(8):237–40.PubMed
22.
go back to reference O’Donnell CP, Stone R, Morley C. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002;110(5):e52.CrossRefPubMed O’Donnell CP, Stone R, Morley C. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002;110(5):e52.CrossRefPubMed
23.
go back to reference Turner S. Unregistered and off-label drug use in paediatric inpatients. Aust J Hosp Pharm. 1999;29(5):265–8.CrossRef Turner S. Unregistered and off-label drug use in paediatric inpatients. Aust J Hosp Pharm. 1999;29(5):265–8.CrossRef
24.
go back to reference Ballard CDJ, Peterson GM, Thompson AJ, Beggs SA. Off-label use of medicines in paediatric inpatients at an Australian teaching hospital. J Paediatr Child Health. 2013;49(1):38–42.CrossRefPubMed Ballard CDJ, Peterson GM, Thompson AJ, Beggs SA. Off-label use of medicines in paediatric inpatients at an Australian teaching hospital. J Paediatr Child Health. 2013;49(1):38–42.CrossRefPubMed
25.
go back to reference Gavrilov V, Berkovitch M, Ling G, Brenner-Zadda G, Lifshitz M, Gorodischer R. Unapproved prescriptions in two pediatric intensive care units in Israel. Curr Ther Res Clin Exp. 2003;64(9):734–42.CrossRefPubMedPubMedCentral Gavrilov V, Berkovitch M, Ling G, Brenner-Zadda G, Lifshitz M, Gorodischer R. Unapproved prescriptions in two pediatric intensive care units in Israel. Curr Ther Res Clin Exp. 2003;64(9):734–42.CrossRefPubMedPubMedCentral
26.
go back to reference Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002;19(2):67–72.CrossRefPubMed Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002;19(2):67–72.CrossRefPubMed
27.
go back to reference Gavrilov V, Lifshitz M, Levy J, Gorodischer R. Unlicensed and off-label medication use in a general pediatrics ambulatory hospital unit in Israel. Isr Med Assoc J. 2000;2(8):595–7.PubMed Gavrilov V, Lifshitz M, Levy J, Gorodischer R. Unlicensed and off-label medication use in a general pediatrics ambulatory hospital unit in Israel. Isr Med Assoc J. 2000;2(8):595–7.PubMed
29.
go back to reference De Bruyne P, Christiaens T, Boussery K, Mehuys E, Van Winckel M. Are antihistamines effective in children? A review of the evidence. Arch Dis Child. 2017;102(1):56–60.CrossRefPubMed De Bruyne P, Christiaens T, Boussery K, Mehuys E, Van Winckel M. Are antihistamines effective in children? A review of the evidence. Arch Dis Child. 2017;102(1):56–60.CrossRefPubMed
30.
go back to reference van der Zanden TM, de Wildt SN, Liem Y, de Offringa M, Hoog M, Dutch Paediatric Pharmacotherapy Expertise Network NKFK (Nederlands Kenniscentrum voor Farmacotherapie bij Kinderen). Developing a paediatric drug formulary for the Netherlands. Arch Dis Child. 2017;102(4):357–61.CrossRefPubMed van der Zanden TM, de Wildt SN, Liem Y, de Offringa M, Hoog M, Dutch Paediatric Pharmacotherapy Expertise Network NKFK (Nederlands Kenniscentrum voor Farmacotherapie bij Kinderen). Developing a paediatric drug formulary for the Netherlands. Arch Dis Child. 2017;102(4):357–61.CrossRefPubMed
31.
go back to reference Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Pediatrics. 2003;112(5):e354.CrossRefPubMed Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Pediatrics. 2003;112(5):e354.CrossRefPubMed
Metadata
Title
Unlicensed and Off-Label Medication Use in Pediatric and Neonatal Intensive Care Units: No Change Over a Decade
Authors
Hadar Nir-Neuman
Ibrahim Abu-Kishk
Michal Toledano
Eli Heyman
Tomer Ziv-Baran
Matitiahu Berkovitch
Publication date
01-07-2018
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 7/2018
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-018-0732-y

Other articles of this Issue 7/2018

Advances in Therapy 7/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.